Oslo, Norway, August 27th, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announces its second quarter results for 2020.

Highlights:

Expansion of Vaccibody’s strategic focus to include Infectious Diseases

Appointment of Gunnstein Norheim, Ph.D., as Director Infectious Diseases leading this new initiative

VB C-02 trial with VB10.16 in combination with Roche’s immune-checkpoint inhibitor atezolizumab in advanced cervical cancer patients approved in all six participating countries, including Norway


Highlights after June 30th, 2020:

Dosing of first patient in VB C-02 Phase II clinical trial with VB10.16 in combination with Roche’s immune-checkpoint inhibitor atezolizumab in advanced cervical cancer

Vaccibody and Nektar Therapeutics dose first patient in Phase I/IIa trial arm evaluating VB10.NEO in combination with bempegaldesleukin (NKTR-214) and immune-checkpoint inhibitor in patients with head and neck cancer

Finalization of patient enrolment in VB N-01 Phase I/IIa clinical trial with VB10.NEO neoantigen cancer vaccine in locally advanced or metastatic cancer patients

Michael Engsig, Chief Executive Officer at Vaccibody, comments:
“This has been a very strong quarter in terms of bringing our projects forward.  With the VB C-02 trial in advanced cervical cancer receiving approvals from relevant regulatory authorities in all the participating countries, followed by finalizing enrolment of the VB N-01 trial, this emphasizes our team’s ability to keep our operations running in spite of the challenging Covid-19 situation”

Contact:
CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
E: mengsig@vaccibody.com